MX347309B - Solucion para administracion oral. - Google Patents

Solucion para administracion oral.

Info

Publication number
MX347309B
MX347309B MX2014004529A MX2014004529A MX347309B MX 347309 B MX347309 B MX 347309B MX 2014004529 A MX2014004529 A MX 2014004529A MX 2014004529 A MX2014004529 A MX 2014004529A MX 347309 B MX347309 B MX 347309B
Authority
MX
Mexico
Prior art keywords
acid
oral administration
solution
salt
compound
Prior art date
Application number
MX2014004529A
Other languages
English (en)
Other versions
MX2014004529A (es
Inventor
Okamoto Ayako
Original Assignee
Otsuka Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otsuka Pharma Co Ltd filed Critical Otsuka Pharma Co Ltd
Publication of MX2014004529A publication Critical patent/MX2014004529A/es
Publication of MX347309B publication Critical patent/MX347309B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/191—Carboxylic acids, e.g. valproic acid having two or more hydroxy groups, e.g. gluconic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Psychiatry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se proporciona una solución adecuada para la administración oral de 7-[4-(4-benzo[b]tiofen-4-il-piperazin-1-il)butoxi]-1H-quinolin- 2-ona (compuesto (I)) o una sal del mismo. Una solución para administración oral que contiene el compuesto (I) o una sal del mismo, y al menos un compuesto seleccionado del grupo que consiste en ácido láctico, ácido fosfórico, ácido glicólico, ácido málico, ácido tartárico, ácido cítrico, ácido succínico y ácido acético y que tiene un pH de 2.5 - 4.5.
MX2014004529A 2011-10-19 2012-10-19 Solucion para administracion oral. MX347309B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161548859P 2011-10-19 2011-10-19
PCT/JP2012/077668 WO2013058411A1 (en) 2011-10-19 2012-10-19 Solution for oral administration

Publications (2)

Publication Number Publication Date
MX2014004529A MX2014004529A (es) 2014-08-01
MX347309B true MX347309B (es) 2017-04-21

Family

ID=47178263

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014004529A MX347309B (es) 2011-10-19 2012-10-19 Solucion para administracion oral.

Country Status (35)

Country Link
US (8) US20140303183A1 (es)
EP (1) EP2768508B1 (es)
JP (1) JP6077534B2 (es)
KR (1) KR101856283B1 (es)
CN (2) CN103889426A (es)
AR (1) AR088372A1 (es)
AU (2) AU2012326978B2 (es)
BR (1) BR112014009330A2 (es)
CA (1) CA2851999C (es)
CL (1) CL2014000967A1 (es)
CO (1) CO6950486A2 (es)
CY (1) CY1117794T1 (es)
DK (1) DK2768508T3 (es)
EA (2) EA202190445A2 (es)
ES (1) ES2583137T3 (es)
HR (1) HRP20160989T1 (es)
HU (1) HUE028869T2 (es)
IL (1) IL231988A (es)
IN (1) IN2014DN02987A (es)
JO (1) JO3190B1 (es)
LT (1) LT2768508T (es)
ME (1) ME02459B (es)
MX (1) MX347309B (es)
MY (1) MY169096A (es)
PH (1) PH12014500816A1 (es)
PL (1) PL2768508T3 (es)
PT (1) PT2768508T (es)
RS (1) RS54967B1 (es)
SG (1) SG11201401273SA (es)
SI (1) SI2768508T1 (es)
SM (1) SMT201600341B (es)
TW (2) TWI679977B (es)
UA (1) UA111506C2 (es)
WO (1) WO2013058411A1 (es)
ZA (1) ZA201402669B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20200109A1 (ar) 2012-04-23 2017-06-16 Otsuka Pharma Co Ltd مستحضر قابل للحقن
JP6203682B2 (ja) * 2013-07-10 2017-09-27 共和薬品工業株式会社 アリピプラゾール含有水性液剤
RU2627423C1 (ru) * 2016-06-29 2017-08-08 Общество С Ограниченной Ответственностью "Валента-Интеллект" Фармацевтическая композиция для лечения инфекционно-воспалительных заболеваний местного применения и способ ее получения и применения
WO2017095265A1 (ru) * 2015-12-01 2017-06-08 Общество С Ограниченной Ответственностью "Валента-Интеллект" Фармацевтическая композиция для лечения инфекционно-воспалительных заболеваний местного применения и способ ее получения и применения
UA124498C2 (uk) * 2015-12-01 2021-09-29 Общєство С Огранічєнной Отвєтствєнностью "Валєнта-Інтєллєкт" Фармацевтична композиція для лікування інфекційно-запальних захворювань місцевого застосування і спосіб її одержання та застосування (варіанти)
RU2633635C1 (ru) * 2016-06-29 2017-10-16 Общество С Ограниченной Ответственностью "Валента-Интеллект" Фармацевтическая композиция для лечения инфекционно-воспалительных заболеваний местного применения и способ ее получения и применения
JP6786240B2 (ja) * 2016-03-31 2020-11-18 小林製薬株式会社 粘性経口組成物
US11013702B2 (en) * 2017-10-10 2021-05-25 Vertice Pharma, Llc Midodrine hydrochloride oral solution and uses thereof
WO2021029020A1 (ja) * 2019-08-13 2021-02-18 大塚製薬株式会社 経口医薬組成物
JP2021115288A (ja) * 2020-01-28 2021-08-10 青葉化成株式会社 液状組成物および液状医療材料
WO2022006205A1 (en) 2020-06-30 2022-01-06 Vireo Systems, Inc. Compositions and methods for treatment of vaginal infections
JP2023532089A (ja) * 2020-06-30 2023-07-26 ビレオ システムズ インコーポレイテッド 臭気及びかゆみを制御するための組成物並びにその投与方法及び投与装置
CN115192548A (zh) * 2021-04-13 2022-10-18 上海博志研新药物技术有限公司 一种布瑞哌唑口溶膜组合物、其制备方法及应用
CN115414322A (zh) * 2022-07-05 2022-12-02 杭州民生药物研究院有限公司 一种富马酸卢帕他定口服液体制剂及其制备工艺
CN116966140A (zh) * 2023-08-18 2023-10-31 四川阿赛斯生物科技有限公司 一种含有布瑞哌唑的口服溶液及其制备方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1420077A (en) * 1972-04-14 1976-01-07 Unilever Ltd Process for imparting or enhancing fresh cheese flavour in a food digital transmission systems
MY129350A (en) * 2001-04-25 2007-03-30 Bristol Myers Squibb Co Aripiprazole oral solution
US7439251B2 (en) * 2002-05-03 2008-10-21 Israel Institute For Biological Research Methods and compositions for treatment of central and peripheral nervous system disorders and novel compounds useful therefor
WO2005102369A1 (ja) * 2004-04-22 2005-11-03 Dainippon Sumitomo Pharma Co., Ltd. 細菌細胞壁骨格成分を含有する製剤
JP4315393B2 (ja) 2005-04-14 2009-08-19 大塚製薬株式会社 複素環化合物
TWI320783B (en) * 2005-04-14 2010-02-21 Otsuka Pharma Co Ltd Heterocyclic compound
ES2390353T3 (es) * 2005-06-13 2012-11-12 Dainippon Sumitomo Pharma Co., Ltd. Preparación de disolución
EP1948133B1 (en) * 2005-09-01 2011-06-29 BAXTER INTERNATIONAL INC. (a Delaware corporation) Argatroban formulation comprising an acid as solubilizer
CA2659390A1 (en) * 2006-07-31 2008-02-07 Asubio Pharma Co., Ltd. Liquid preparation
MX2010002927A (es) * 2007-09-17 2010-06-01 Schering Corp Formulacion que contiene un compueto inhibidor de quinasa dependiente de ciclina y metodo para tratar tumores utilizando el mismo.
KR101599560B1 (ko) 2007-09-21 2016-03-03 아스트라제네카 아베 비경구 투여에 적합한 세펨 유도체를 함유하는 가용성 제형
US8263652B2 (en) * 2007-10-31 2012-09-11 Sk Biopharmaceuticals Co., Ltd. Stabilized pediatric suspension of carisbamate
SG184879A1 (en) * 2010-08-24 2012-11-29 Otsuka Pharma Co Ltd Suspension and cake composition containing carbostyryl derivative and silicone oil and/or silicone oil derivative
CN102119922A (zh) * 2011-03-03 2011-07-13 天津市炜杰科技有限公司 以酸作为增溶剂的21(s)阿加曲班静脉注射液
JOP20120083B1 (ar) * 2011-04-05 2021-08-17 Otsuka Pharma Co Ltd توليفات تشتمل على بريكس ببرازول أو ملح منه وعقار ثاني للاستخدام في علاج اضطراب cns

Also Published As

Publication number Publication date
TWI679977B (zh) 2019-12-21
SG11201401273SA (en) 2014-05-29
HK1196773A1 (zh) 2014-12-24
ES2583137T3 (es) 2016-09-19
AU2012326978B2 (en) 2017-08-31
IL231988A (en) 2017-09-28
US20210236483A1 (en) 2021-08-05
MY169096A (en) 2019-02-18
JP6077534B2 (ja) 2017-02-08
JO3190B1 (ar) 2018-03-08
EP2768508A1 (en) 2014-08-27
ZA201402669B (en) 2015-09-30
IN2014DN02987A (es) 2015-05-08
PH12014500816A1 (en) 2014-05-19
TW201330873A (zh) 2013-08-01
IL231988A0 (en) 2014-05-28
HRP20160989T1 (hr) 2016-10-07
US20250099460A1 (en) 2025-03-27
UA111506C2 (uk) 2016-05-10
CO6950486A2 (es) 2014-05-20
KR20140083032A (ko) 2014-07-03
EP2768508B1 (en) 2016-07-06
US20170182036A1 (en) 2017-06-29
CN103889426A (zh) 2014-06-25
TWI632921B (zh) 2018-08-21
CL2014000967A1 (es) 2014-10-03
JP2014530801A (ja) 2014-11-20
EA202190445A2 (ru) 2021-08-31
NZ623523A (en) 2015-12-24
LT2768508T (lt) 2016-09-12
CN107823131A (zh) 2018-03-23
PL2768508T3 (pl) 2016-12-30
TW201737916A (zh) 2017-11-01
HUE028869T2 (en) 2017-01-30
AU2012326978A1 (en) 2014-05-22
US20180271858A1 (en) 2018-09-27
PT2768508T (pt) 2016-08-17
SMT201600341B (it) 2016-11-10
WO2013058411A1 (en) 2013-04-25
CA2851999C (en) 2020-01-07
AU2017213570A1 (en) 2017-08-31
KR101856283B1 (ko) 2018-05-09
CY1117794T1 (el) 2017-05-17
ME02459B (me) 2017-02-20
US20160213665A1 (en) 2016-07-28
US20140303183A1 (en) 2014-10-09
BR112014009330A2 (pt) 2017-04-11
CA2851999A1 (en) 2013-04-25
US20240009186A1 (en) 2024-01-11
AR088372A1 (es) 2014-05-28
EA201490812A1 (ru) 2014-09-30
US20200171023A1 (en) 2020-06-04
SI2768508T1 (sl) 2016-09-30
RS54967B1 (sr) 2016-11-30
MX2014004529A (es) 2014-08-01
DK2768508T3 (en) 2016-08-29

Similar Documents

Publication Publication Date Title
MX347309B (es) Solucion para administracion oral.
MX2012002875A (es) Derivados de 6-amino-quinazolina o 3-ciano-quinolina, metodos de preparacion y usos farmaceuticos de los mismos.
MY148096A (en) 4,5-diphenyl-pyrimidinyl-amino substituted carboxylic acids, method for the production and use thereof as medicaments
PH12012502568A1 (en) Crystalline forms and two solvated forms of 4-amino-5-fluoro-3-[5-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]quinolin-2(1h)-one lactic acid salts
MY148483A (en) 4,5-diphenyl-pyrimidinyl-oxy or-mercapto substituted carboxylic acids, method for the production and use thereof as medicaments
PH12012500519A1 (en) Substituted carbamoylmethylamino acetic acid derivatives as novel nep inhibitors
MX2021008356A (es) Inhibidores de jak2 y alk2 y metodos para su uso.
MX2014001595A (es) Compuestos de imidazol, composiciones y metodos de uso.
UA105229C2 (uk) Фармацевтичний склад
WO2012054110A3 (en) Compounds and methods for inhibiting phosphate transport
MX348228B (es) Cristal de derivados de 6,7-insaturado-7-carbamoil morfinano y metodo para producir el mismo.
MY149648A (en) Carboxylalkylene-phenyl)-phenyl-oxalamides, method for the production thereof, and use of same as a medicament
WO2012006474A3 (en) Compounds and methods for inhibiting phosphate transport
UA93393C2 (uk) 1,3-діоксанкарбонові кислоти
UA99787C2 (en) Lactams as beta secretase inhibitors
MY155230A (en) Sulfoximine-substituted aniline pyrimidine derivatives as cdk inhibitors, their manufacture and use as medicine
MX2013008340A (es) Novedosas 4-amino-n-hidroxi-benzamidas para el tratamiento de cancer.
IN2012DN01292A (es)
PH12012500992A1 (en) Compound, certain novel forms thereof, pharmaceutical compositions thereof and methods for preparation and use
MY160005A (en) 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene citrate salt
TH148781A (th) สารละลายสำหรับการให้ทางช่องปาก
UA98311C2 (ru) Соединение 2-алкилиндазола для лечения определенных расстройств, связанных с цнс, способ его получения (варианты) и фармацевтическая композиция на его основе
TH97363B (th) สารละลายสำหรับการให้ทางช่องปาก
HK1184972A1 (zh) 化合物及用於抑制磷酸盐转运的方法
TN2010000418A1 (en) Crystalline forms and two solvated forms of 4-amino-5-fluoro-3-[5-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]quinolin-2(1h)-one lactic acid salts

Legal Events

Date Code Title Description
FG Grant or registration